Ibiglustat

Overview

Ibiglustat (Venglustat) is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease.

Application

Products | Products > Disease Areas > Parkinson's Disease | Products > Disease Areas > Infection | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > SARS-CoV-2 Infection | Products > Signaling Pathways > Neuronal Signaling | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > Glucosylceramide Synthase (GCS)

Product Information

• Catalog No.: HY-16743
• CAS No.: 1401090-53-6
• Molecular Formula: C20H24FN3O2S
• Molecular Weight: 389.49
• Purity: 99.86%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
• Solubility: ≥ 2.5 mg/mL (6.42 mM); Clear solution
• Availability: In-stock

Source

Original product source